Symbols / TCRT $3.26 -1.51%
TCRT Chart
About
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.28M |
| Enterprise Value | 5.34M | Income | -4.03M | Sales | 6.00K |
| Book/sh | 1.27 | Cash/sh | 0.87 | Dividend Yield | — |
| Payout | 0.00% | Employees | 1 | IPO | — |
| P/E | — | Forward P/E | -5.43 | PEG | — |
| P/S | 1212.63 | P/B | 2.56 | P/C | — |
| EV/EBITDA | -1.31 | EV/Sales | 889.63 | Quick Ratio | 2.10 |
| Current Ratio | 2.92 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.30 | EPS next Y | -0.60 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-08-14 16:00 | ROA | -69.99% |
| ROE | -145.65% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -678.83% | Profit Margin | 0.00% | Shs Outstand | 2.23M |
| Shs Float | 1.74M | Short Float | 1.60% | Short Ratio | 2.53 |
| Short Interest | — | 52W High | 6.20 | 52W Low | 1.31 |
| Beta | -1.22 | Avg Volume | 25.87K | Volume | 2.55K |
| Target Price | — | Recom | None | Prev Close | $3.31 |
| Price | $3.26 | Change | -1.51% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$3.30
Latest analyst target
3. DCF / Fair value
$-6.41
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.30
Low
—
High
—
Mean
—
- TCRT,MLAC Revenue Breakdown - Finviz hu, 12 Mar 2026 21
- Non-hormonal obesity pill helps mice lose weight, improve liver health - Stock Titan Mon, 02 Mar 2026 08
- TCRT Stock Surge: What To Expect Next? - StocksToTrade hu, 09 Oct 2025 07
- Alaunos Therapeutics regains Nasdaq compliance after equity increase - Investing.com Wed, 20 Aug 2025 07
- Alaunos Updates Governance, Ends Cantor Advisory Agreement - TipRanks hu, 08 Jan 2026 08
- TCRT Technical Analysis & Price Forecast - Intellectia AI ue, 10 Mar 2026 04
- TCRT Stock’s Rollercoaster: What’s Next? - timothysykes.com hu, 09 Oct 2025 07
- Alaunos Therapeutics Appoints Holger Weis as New CEO - The Globe and Mail hu, 03 Jul 2025 07
- Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance Fri, 04 Apr 2025 07
- PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies - marketscreener.com Wed, 18 Jun 2025 07
- Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65% - Nasdaq Wed, 16 Aug 2023 07
- PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT) - Yahoo Finance Wed, 14 May 2025 07
- TCRT Stock Price and Chart — NASDAQ:TCRT - TradingView hu, 03 Feb 2022 03
- Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga hu, 09 Oct 2025 07
- Why Is Ebix (EBIX) Stock Down 47% Today? - InvestorPlace Mon, 18 Dec 2023 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5622 | 16248 | — | Stock Award(Grant) at price 2.89 per share. | POSTMA ROBERT W. | Director | — | 2026-01-12 00:00:00 | D |
| 1 | 5839 | 16875 | — | Stock Award(Grant) at price 2.89 per share. | VIESER JAIME W. | Director | — | 2026-01-12 00:00:00 | D |
| 2 | 5406 | 15623 | — | Stock Award(Grant) at price 2.89 per share. | JERMAN MICHAEL ALLEN | Director | — | 2026-01-12 00:00:00 | D |
| 3 | 5142 | 16249 | — | Stock Award(Grant) at price 3.16 per share. | POSTMA ROBERT W. | Director | — | 2025-11-21 00:00:00 | D |
| 4 | 5340 | 16874 | — | Stock Award(Grant) at price 3.16 per share. | VIESER JAIME W. | Director | — | 2025-11-21 00:00:00 | D |
| 5 | 4183 | 13218 | — | Stock Award(Grant) at price 3.16 per share. | JERMAN MICHAEL ALLEN | Director | — | 2025-11-21 00:00:00 | D |
| 6 | 10775 | — | — | Stock Award(Grant) at price 0.00 per share. | GROENEWALD FERDINAND | Officer | — | 2025-08-18 00:00:00 | D |
| 7 | 4050 | — | — | Stock Award(Grant) at price 0.00 per share. | POSTMA ROBERT W. | Director | — | 2025-07-03 00:00:00 | D |
| 8 | 3400 | — | — | Stock Award(Grant) at price 0.00 per share. | VIESER JAIME W. | Director | — | 2025-07-03 00:00:00 | D |
| 9 | 20804 | 60748 | — | Stock Award(Grant) at price 2.92 per share. | POSTMA ROBERT W. | Director | — | 2025-04-11 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -4.68M | -25.13M | -31.95M | -74.22M |
| TotalUnusualItems | 0.00 | -5.77M | 133.00K | -740.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -5.77M | 133.00K | -740.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -4.68M | -35.14M | -37.73M | -78.75M |
| ReconciledDepreciation | 2.00K | 2.31M | 2.76M | 2.60M |
| EBITDA | -4.68M | -30.90M | -31.82M | -74.97M |
| EBIT | -4.68M | -33.22M | -34.58M | -77.56M |
| NetInterestIncome | 0.00 | -1.92M | -3.15M | -1.19M |
| InterestExpense | 0.00 | 1.92M | 3.15M | 1.19M |
| NormalizedIncome | -4.68M | -29.37M | -37.86M | -78.01M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -4.68M | -35.14M | -37.73M | -78.75M |
| TotalExpenses | 4.82M | 28.50M | 38.16M | 77.21M |
| TotalOperatingIncomeAsReported | -4.81M | -34.27M | -35.10M | -77.55M |
| DilutedAverageShares | 1.60M | 1.60M | 1.45M | 1.43M |
| BasicAverageShares | 1.60M | 1.60M | 1.45M | 1.43M |
| DilutedEPS | -2.92 | -21.97 | -25.50 | -55.50 |
| BasicEPS | -2.92 | -21.97 | -25.50 | -55.50 |
| DilutedNIAvailtoComStockholders | -4.68M | -35.14M | -37.73M | -78.75M |
| NetIncomeCommonStockholders | -4.68M | -35.14M | -37.73M | -78.75M |
| NetIncome | -4.68M | -35.14M | -37.73M | -78.75M |
| NetIncomeIncludingNoncontrollingInterests | -4.68M | -35.14M | -37.73M | -78.75M |
| NetIncomeContinuousOperations | -4.68M | -35.14M | -37.73M | -78.75M |
| PretaxIncome | -4.68M | -35.14M | -37.73M | -78.75M |
| OtherIncomeExpense | 133.00K | -4.73M | 662.00K | -753.00K |
| OtherNonOperatingIncomeExpenses | 133.00K | 1.05M | 529.00K | -13.00K |
| SpecialIncomeCharges | 0.00 | -5.77M | 133.00K | -740.00K |
| OtherSpecialCharges | -298.00K | -133.00K | ||
| ImpairmentOfCapitalAssets | 0.00 | 4.80M | 0.00 | 740.00K |
| RestructuringAndMergernAcquisition | 0.00 | 1.27M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 0.00 | -1.92M | -3.15M | -1.19M |
| InterestExpenseNonOperating | 0.00 | 1.92M | 3.15M | 1.19M |
| OperatingIncome | -4.81M | -28.49M | -35.24M | -76.81M |
| OperatingExpense | 4.82M | 28.50M | 38.16M | 77.21M |
| ResearchAndDevelopment | 362.00K | 16.28M | 25.02M | 49.64M |
| SellingGeneralAndAdministration | 4.46M | 12.22M | 13.14M | 27.56M |
| GeneralAndAdministrativeExpense | 4.46M | 12.22M | 13.14M | 27.56M |
| OtherGandA | 4.46M | 12.22M | 13.14M | 27.56M |
| TotalRevenue | 10.00K | 5.00K | 2.92M | 398.00K |
| OperatingRevenue | 10.00K | 5.00K | 2.92M | 398.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 1.60M | 1.60M | 1.60M | 1.44M |
| ShareIssued | 1.60M | 1.60M | 1.60M | 1.44M |
| TotalDebt | 0.00 | 19.51M | 29.36M | |
| TangibleBookValue | 2.06M | 6.31M | 38.55M | 58.06M |
| InvestedCapital | 2.06M | 6.31M | 55.32M | 82.17M |
| WorkingCapital | 2.06M | 6.30M | 29.63M | 62.79M |
| NetTangibleAssets | 2.06M | 6.31M | 38.55M | 58.06M |
| CapitalLeaseObligations | 0.00 | 2.75M | 5.25M | |
| CommonStockEquity | 2.06M | 6.31M | 38.55M | 58.06M |
| TotalCapitalization | 2.06M | 6.31M | 38.55M | 74.31M |
| TotalEquityGrossMinorityInterest | 2.06M | 6.31M | 38.55M | 58.06M |
| StockholdersEquity | 2.06M | 6.31M | 38.55M | 58.06M |
| RetainedEarnings | -920.45M | -915.77M | -880.63M | -842.85M |
| AdditionalPaidInCapital | 922.51M | 922.07M | 919.17M | 900.69M |
| CapitalStock | 2.00K | 2.00K | 16.00K | 216.00K |
| CommonStock | 2.00K | 2.00K | 16.00K | 216.00K |
| TotalLiabilitiesNetMinorityInterest | 692.00K | 1.96M | 26.38M | 36.81M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 2.22M | 20.77M |
| OtherNonCurrentLiabilities | 28.00K | -1.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 2.19M | 20.77M | |
| LongTermCapitalLeaseObligation | 0.00 | 2.19M | 4.52M | |
| LongTermDebt | 16.25M | |||
| CurrentLiabilities | 692.00K | 1.96M | 24.17M | 16.04M |
| CurrentDebtAndCapitalLeaseObligation | 17.32M | 8.60M | ||
| CurrentCapitalLeaseObligation | 0.00 | 558.00K | 729.00K | |
| CurrentDebt | 16.77M | 7.87M | ||
| OtherCurrentBorrowings | 16.77M | 7.87M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 0.00 | 43.00K | 1.16M | 1.92M |
| PayablesAndAccruedExpenses | 692.00K | 1.91M | 5.68M | 5.52M |
| CurrentAccruedExpenses | 176.00K | 1.30M | 4.29M | 4.15M |
| Payables | 516.00K | 616.00K | 1.39M | 1.37M |
| TotalTaxPayable | 0.00 | |||
| AccountsPayable | 516.00K | 616.00K | 1.39M | 1.37M |
| TotalAssets | 2.75M | 8.26M | 64.94M | 94.86M |
| TotalNonCurrentAssets | 0.00 | 2.00K | 11.14M | 16.03M |
| OtherNonCurrentAssets | 500.00K | 631.00K | ||
| NonCurrentPrepaidAssets | 0.00 | 42.00K | 42.00K | |
| NetPPE | 0.00 | 2.00K | 10.60M | 15.36M |
| AccumulatedDepreciation | -15.00K | -13.00K | -9.81M | -7.41M |
| GrossPPE | 15.00K | 15.00K | 20.40M | 22.77M |
| Leases | 0.00 | 9.56M | 9.47M | |
| ConstructionInProgress | 5.23M | 5.11M | ||
| OtherProperties | 5.23M | 5.11M | ||
| MachineryFurnitureEquipment | 15.00K | 15.00K | 3.47M | 3.77M |
| BuildingsAndImprovements | 0.00 | 2.14M | 4.42M | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 2.75M | 8.26M | 53.80M | 78.83M |
| OtherCurrentAssets | 1.66M | 2.20M | 799.00K | 1.67M |
| RestrictedCash | 0.00 | 13.94M | 0.00 | |
| PrepaidAssets | 1.67M | |||
| Receivables | 5.00K | 1.00K | 4.00K | 1.11M |
| AccountsReceivable | 5.00K | 1.00K | 4.00K | 1.11M |
| CashCashEquivalentsAndShortTermInvestments | 1.09M | 6.06M | 39.06M | 76.05M |
| CashAndCashEquivalents | 1.09M | 6.06M | 39.06M | 76.05M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -4.97M | -30.34M | -29.45M | -64.79M |
| RepurchaseOfCapitalStock | 0.00 | -45.00K | 0.00 | |
| RepaymentOfDebt | 0.00 | -18.11M | -8.33M | 0.00 |
| IssuanceOfDebt | 0.00 | 25.00M | ||
| IssuanceOfCapitalStock | 0.00 | 92.00K | 14.72M | 0.00 |
| CapitalExpenditure | -197.00K | -216.00K | -3.32M | |
| InterestPaidSupplementalData | 0.00 | 2.06M | 2.17M | 630.00K |
| EndCashPosition | 1.09M | 6.06M | 53.00M | 76.05M |
| BeginningCashPosition | 6.06M | 53.00M | 76.05M | 115.07M |
| ChangesInCash | -4.97M | -46.93M | -23.06M | -39.02M |
| FinancingCashFlow | 0.00 | -18.14M | 6.37M | 25.78M |
| CashFlowFromContinuingFinancingActivities | 0.00 | -18.14M | 6.37M | 25.78M |
| NetOtherFinancingCharges | -125.00K | -260.00K | ||
| ProceedsFromStockOptionExercised | 0.00 | 21.00K | 1.04M | |
| NetCommonStockIssuance | 0.00 | 92.00K | 14.68M | 0.00 |
| CommonStockPayments | 0.00 | -45.00K | 0.00 | |
| CommonStockIssuance | 0.00 | 92.00K | 14.72M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | -18.11M | -8.33M | 25.00M |
| NetLongTermDebtIssuance | 0.00 | -18.11M | -8.33M | 25.00M |
| LongTermDebtPayments | 0.00 | -18.11M | -8.33M | 0.00 |
| LongTermDebtIssuance | 0.00 | 25.00M | ||
| InvestingCashFlow | 0.00 | 1.35M | -193.00K | -3.32M |
| CashFlowFromContinuingInvestingActivities | 0.00 | 1.35M | -193.00K | -3.32M |
| NetPPEPurchaseAndSale | 0.00 | 1.35M | -193.00K | -3.32M |
| SaleOfPPE | 0.00 | 1.54M | 23.00K | 0.00 |
| PurchaseOfPPE | 0.00 | -197.00K | -216.00K | -3.32M |
| OperatingCashFlow | -4.97M | -30.14M | -29.23M | -61.47M |
| CashFlowFromContinuingOperatingActivities | -4.97M | -30.14M | -29.23M | -61.47M |
| ChangeInWorkingCapital | -729.00K | -6.25M | 870.00K | 3.14M |
| ChangeInOtherCurrentLiabilities | 0.00 | -138.00K | -542.00K | 434.00K |
| ChangeInOtherCurrentAssets | 500.00K | 131.00K | 201.00K | |
| ChangeInPayablesAndAccruedExpense | -1.26M | -4.76M | -693.00K | -10.24M |
| ChangeInAccruedExpense | -1.16M | -3.99M | -668.00K | -10.51M |
| ChangeInPayable | -100.00K | -773.00K | -25.00K | 274.00K |
| ChangeInAccountPayable | -100.00K | -773.00K | -25.00K | 274.00K |
| ChangeInPrepaidAssets | 539.00K | -1.36M | 867.00K | 9.19M |
| ChangeInReceivables | -4.00K | 3.00K | 1.11M | 3.56M |
| OtherNonCashItems | 1.33M | 1.33M | 31.00K | |
| StockBasedCompensation | 435.00K | 2.80M | 3.53M | 10.77M |
| AssetImpairmentCharge | 0.00 | 4.80M | 0.00 | 740.00K |
| DepreciationAmortizationDepletion | 2.00K | 2.31M | 2.76M | 2.60M |
| DepreciationAndAmortization | 2.00K | 2.31M | 2.76M | 2.60M |
| Depreciation | 2.00K | 2.31M | 2.76M | 2.60M |
| OperatingGainsLosses | 7.00K | 7.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 7.00K | 7.00K | 0.00 |
| NetIncomeFromContinuingOperations | -4.68M | -35.14M | -37.73M | -78.75M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TCRT
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|